Article content material
HYDERABAD, India, Aug. 21, 2023 (GLOBE NEWSWIRE) — Sai Life Sciences, a worldwide Contract Research, Development & Manufacturing Organization (CRO-CDMO), entered its Silver Jubilee yr with aplomb, surpassing its imaginative and prescient of supporting international innovator companions in bringing 25 new medicines to market by 2025. The corporate crossed this milestone two years forward of schedule and is poised to maintain this momentum on the again of a powerful portfolio of molecules at varied levels of scientific improvement.
Article content material
Marking the entry into its 25th yr, the Chairman Dr. Ok. Ranga Raju and members of the senior administration inaugurated a number of new laboratories and amenities, and a grand new entrance to its 12-acre built-in R&D campus in Hyderabad. Notable among the many new laboratories have been a doubling of its DMPK footprint and a sizeable growth of analytical R&D capability for its Discovery Chemistry providers.
Article content material
Expressing delight on the event,
Dr. Ok. Ranga Raju, Founder Chairman, stated, “During the last 24 years, due to the belief that our shoppers have reposed in us, Sai Life Sciences has grown from a small lab with two fume hoods into a worldwide CRO-CDMO offering the whole vary of providers alongside the drug discovery journey with world-class amenities throughout three continents and propelled by a 2,900-strong expertise pool. As we glance to the longer term, we rededicate ourselves to working with international innovator companions to speed up a more healthy future.”
The event additionally formally concluded the corporate’s Sai Nxt initiative, which witnessed strategic investments of over US$130 million throughout 2019-2023, enabling the corporate to reinforce capability, scale up operations, broaden into new geographies, develop the scientific expertise base, and lift the general bar for high quality, compliance, and efficiency.
Article content material
Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, stated, “In 2016, we set a imaginative and prescient for ourselves to assist our international innovator companions in bringing 25 new medicines to life by 2025. I’m delighted to share that we’ve surpassed this aim two years forward of schedule. There can’t be something extra gratifying for us as an organization as we enter our silver jubilee yr.”
The corporate has introduced a collection of initiatives as a part of its 25th yr celebrations culminating in August 2024, to commemorate the corporate’s journey, acknowledge contributions of assorted people, and have interaction all its stakeholders in charting a collective future.
Sauri Gudlavalleti, Chief Working Officer of Sai Life Sciences, stated, “We’re excited concerning the subsequent part of our development. We’ll actively have interaction with our shoppers, companions, and staff to chart a journey that may allow us to meaningfully affect the way forward for healthcare.”
About Sai Life Sciences:
Sai Life Sciences is a full-service CRO-CDMO that works with the innovator pharma and biotech firms globally, to speed up the invention, improvement, and commercialisation of advanced small molecules. The corporate has 2,900 staff throughout its amenities in India, UK and USA. Sai Life Sciences is privately held and backed by international buyers, TPG Capital and HBM Healthcare Investments. https://www.sailife.com/
A photograph accompanying this announcement is on the market at https://www.globenewswire.com/NewsRoom/AttachmentNg/8841bd0e-378a-4f69-85b2-fb08f49c59b0
Source link
